Sihuan Pharma received permission from the SFDA to begin clinical trials of pinoxacin hydrochloride, a Category 1.1 drug. The drug is a DPP-4 inhibitor that is intended for type 2 diabetics. The Beijing-based company said it would start a Phase I trial in the first half of 2013. In January, Sihuan announced approval to begin clinical trials of another Category 1.1 drug, an innovative carbapenem antibiotic known as benapenum. So far, four of Sihuan’s Category 1 drugs have received approval for human testing. More details.... Stock Symbol: (HK: 0460) Share this with colleagues: // //